108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
非侵入性脑刺激治疗偏头痛的短期和长期疗效：一项荟萃分析
Authors Liu M , Yong Y, Zou H , Yang L , Qian J
Received 15 April 2025
Accepted for publication 31 July 2025
Published 19 September 2025 Volume 2025:18 Pages 4883—4900
DOI https://doi.org/10.2147/JPR.S529622
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Rune Häckert Christensen
Mengya Liu,1 Yongxia Yong,2 Hui Zou,1 Luping Yang,3 Jinghua Qian1
1School of Sports Medicine and Rehabilitation, Beijing Sport University, Beijing, People’s Republic of China; 2Department of rehabilitation medicine, General Hospital of Western Theater Command, Chengdu, People’s Republic of China; 3Department of Rehabilitation Technology, Sichuan Nursing Vocational College, Chengdu, People’s Republic of China
Correspondence: Jinghua Qian, School of Sports Medicine and Rehabilitation, Beijing Sport University, Beijing, People’s Republic of China, Email jinghuaqian891273@126.com
Purpose: Non-invasive brain stimulation (NIBS) has shown promising potential in the treatment of migraine; however, its short- and long-term efficacy remains uncertain. This meta-analysis evaluated the effects of NIBS on multiple migraine-related clinical outcomes in both short- and long-term follow-ups.
Methods: This PRISMA-compliant review (PROSPERO: CRD42024529488) included RCTs on NIBS for migraine. A comprehensive search was conducted in PubMed, Scopus, The Cochrane, EMBASE, Web of Science, CNKI, and VIP up to April 11, 2024. Outcomes consisted of headache frequency, pain intensity, duration, analgesic intake, and adverse effects. Analyses used RevMan 5.3 and STATA 17.0.
Results: Thirteen studies (596 participants) were included. In terms of short-term outcomes, NIBS significantly reduced headache frequency (SMD = − 1.47, 95% CI: − 2.13 to − 0.82) and pain intensity (SMD = − 2.09, 95% CI: − 3.36 to − 0.83). During long-term follow-up, significant effects were still observed at < 3 months (headache frequency: SMD = − 1.13, 95% CI: − 1.90 to − 0.35; pain intensity: − 0.66 95% CI: − 1.02 to − 0.30) and at 6– 12 months (headache frequency: SMD = − 3.95, 95% CI: − 7.44 to − 0.45; pain intensity: SMD = − 2.55 95% CI: − 4.73 to − 0.36, with no significant improvements at 3– 6 months. NIBS also provided short-term benefits in pain duration and analgesic use. Adverse event rates did not differ between groups. Meta-regression linked target and device to short-term efficacy.
Conclusion: NIBS is an effective, preventive, and safe treatment for migraine but its long-term efficacy is not evident.
Keywords: migraine disorders, non-invasive brain stimulation, NIBS, efficacy
1School of Sports Medicine and Rehabilitation, Beijing Sport University, Beijing, People’s Republic of China; 2Department of rehabilitation medicine, General Hospital of Western Theater Command, Chengdu, People’s Republic of China; 3Department of Rehabilitation Technology, Sichuan Nursing Vocational College, Chengdu, People’s Republic of China
Correspondence: Jinghua Qian, School of Sports Medicine and Rehabilitation, Beijing Sport University, Beijing, People’s Republic of China, Email jinghuaqian891273@126.com
Purpose: Non-invasive brain stimulation (NIBS) has shown promising potential in the treatment of migraine; however, its short- and long-term efficacy remains uncertain. This meta-analysis evaluated the effects of NIBS on multiple migraine-related clinical outcomes in both short- and long-term follow-ups.
Methods: This PRISMA-compliant review (PROSPERO: CRD42024529488) included RCTs on NIBS for migraine. A comprehensive search was conducted in PubMed, Scopus, The Cochrane, EMBASE, Web of Science, CNKI, and VIP up to April 11, 2024. Outcomes consisted of headache frequency, pain intensity, duration, analgesic intake, and adverse effects. Analyses used RevMan 5.3 and STATA 17.0.
Results: Thirteen studies (596 participants) were included. In terms of short-term outcomes, NIBS significantly reduced headache frequency (SMD = − 1.47, 95% CI: − 2.13 to − 0.82) and pain intensity (SMD = − 2.09, 95% CI: − 3.36 to − 0.83). During long-term follow-up, significant effects were still observed at < 3 months (headache frequency: SMD = − 1.13, 95% CI: − 1.90 to − 0.35; pain intensity: − 0.66 95% CI: − 1.02 to − 0.30) and at 6– 12 months (headache frequency: SMD = − 3.95, 95% CI: − 7.44 to − 0.45; pain intensity: SMD = − 2.55 95% CI: − 4.73 to − 0.36, with no significant improvements at 3– 6 months. NIBS also provided short-term benefits in pain duration and analgesic use. Adverse event rates did not differ between groups. Meta-regression linked target and device to short-term efficacy.
Conclusion: NIBS is an effective, preventive, and safe treatment for migraine but its long-term efficacy is not evident.
Keywords: migraine disorders, non-invasive brain stimulation, NIBS, efficacy